Brigatinib Before Brain Irradiation Trial (B3i Trial)
Status:
Recruiting
Trial end date:
2025-07-10
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study of brigatinib alone for patients with brain metastases
from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have
either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or
who have had prior exposure to crizotinib.